EBS
Emergent BioSolutions Inc. · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-27
Figures on this page computed 2026-11-08 12:12 UTC
Last close
5.90USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-27
6.2xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-27
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
7.1%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
21.1%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Growth is the furthest below its sector's middle: 0.32 against 0.47 on the market's range.
- Growth-14.0%32 of 100, below its sector
- Returns on capital10.1%69 of 100, above its sector
- Margins56.1%75 of 100, above its sector
- Price6.2x84 of 100, above its sector
- Safety5.0147 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 1 of 3- Profit on each unit of sales7.1%-1.7%Ahead
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years-14.0%73.1%Behind
Higher is better here.
- Debt against equityn/an/an/a
Lower is better here.
- Gross margin56.1%27.3%Ahead
Higher is better here.
- Price against earnings6.2xn/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against SNDL Inc., EBS is behind on 1 of 3 measures.
Against SNDL Inc., EBS is behind on 1 of 3 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-27
Profit on each unit of sales7.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
Sales growth over five years-14.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
Gross margin56.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD
Price against earnings6.2x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001367644-26-000015
- Reported in
- USD